Iradimed (IRMD) news
Recent news
IradiMed Corporation: Needham initiates coverage with hold rating
Needham & Company has initiated coverage of IradiMed Corporation (NYSE: IRDM) with a "Hold" rating, citing a balanced assessment of the company's current market position and growth prospects. The firm noted that while IradiMed has demonstrated progress in expanding its product portfolio and market…
AInvest Wire · Sep 22, 2026Iradimed Q2 adjusted EPS USD 0.46
AInvest Wire · Jul 31, 2026Iradimed Corp: Continue to gain efficiencies, which we expect will be reflected in a higher gross margin in second half of year
AInvest Wire · Jul 31, 2026Iradimed Corp - reaffirms FY2026 revenue guidance $91 mln-$96 mln, non-GAAP diluted EPS $2.09-$2.24
AInvest Wire · Jul 31, 2026Iradimed Q2 EPS USD 0.41
Iradimed Corporation (NASDAQ: IRMD) reported second-quarter 2026 earnings per share (EPS) of $0.41, reflecting continued growth in its MRI-compatible medical device business. The company, which specializes in non-magnetic intravenous infusion pumps and patient monitoring systems for use during MRI…
AInvest Wire · Jul 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.